Jonah Feldman

Physicians at VCU's Massey Comprehensive Cancer Center explored their experiences using tumor-infiltrating lymphocytes to treat patients with advanced melanoma.

In an interview with Targeted Oncology, David J. Benjamin, MD, discussed findings on the global oncology workforce and their implications of insufficient access to cancer care.

In an interview with Targeted Oncology, Frederick L. Locke, MD, discussed how the elimination of the REMS program for CAR T-cell therapy came about and what effects he hopes this will have on patient access.

Iza-bren shows significant improvement in response rates for recurrent nasopharyngeal carcinoma compared to chemotherapy, offering new hope for patients.

New research shows that adding apalutamide to androgen deprivation therapy significantly improves outcomes for patients with recurrent prostate cancer.

Anbenitamab plus chemotherapy significantly improves survival rates in HER2-positive gastric cancer patients, offering a promising new treatment option.

In an interview with Targeted Oncology, Justin Watts, MD spoke about the long-term durability findings with olutasidenib and the next steps for IDH inhibitors in AML.

In an interview with Targeted Oncology, Justin Watts, MD, discussed the outcomes of a trial of the IDH1 inhibitor olutasidenib in patients with myelodysplastic syndrome.

Treatment strategies for non–small cell lung cancer are increasingly driven by biomarker testing, making rapid and reliable biopsy an area that has attracted new interest among lung cancer specialists.

Experts explore advancements in bronchoscopic biopsies for lung cancer, emphasizing safety, sample adequacy, and the importance of rapid biomarker testing.

Zev A. Wainberg, MD, discussed the significance of the AMPLIFY-201 trial, next steps for this vaccine platform, and the signs of progress he has recently seen in this challenging disease setting.

A multidisciplinary expert panel issued recommendations on the use of bronchoscopic biopsies in terms of safety and sample adequacy for comprehensive biomarker testing.

The vaccine ELI-002 2P showed favorable relapse-free survival and overall survival in patients with pancreatic and colorectal cancer, particularly if they had strong T-cell responses.

Allogeneic cell therapies are advancing in clinical trials, requiring oncologists and pathologists to understand the opportunities they present for patients and the potential challenges from a laboratory perspective.

The FDA approved intravesical mitomycin in non–muscle-invasive bladder cancer as an nonsurgical alternative to transurethral resection of bladder tumors.

A phase 3 trial did not support a transplant-based approach for patients who already achieved MRD negativity or a tandem transplant approach for those who did not achieve prior MRD negativity.

A randomized phase 2 study of a GSK-3ß inhibitor plus gemcitabine/nab-paclitaxel showed survival benefit in patients with untreated metastatic pancreatic ductal adenocarcinoma.

In the phase 3 PANOVA-3 trial, patients who underwent tumor-treating fields therapy had extended overall survival vs standard-of-care gemcitabine plus nab-paclitaxel.

In an interview with Targeted Oncology, C. Ola Langren, MD, PhD, discussed the continuing impact of the groundbreaking FDA ODAC vote, the future of the Miami Myeloma MRD Meeting, and how researchers plan to continue expanding the role of MRD in myeloma and other hematologic malignancies.

In the last year, there has been excitement about the use of MRD in multiple myeloma trials and new approaches to assessing clinical outcomes in patients.

In an interview with Peers & Perspectives in Oncology, John L. Marshall, MD, discussed treatment approaches and sequencing for refractory colorectal cancer.

The phase 2/3 GOG286B reported efficacy findings and new exploratory outcomes on the combination of metformin, paclictaxel, and carboplatin in patients with advanced or recurrent endometrial cancer.

Jennifer Chan, MD, MPH, discussed the recent FDA approval of cabozantinib in pancreatic and extrapancreatic neuroendocrine tumors.

The FDA approved cabozantinib for previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic and extrapancreatic neuroendocrine tumors.

A propensity-score matched cohort study found a significantly reduced risk of recurrence of bladder cancer in patients who had blue light vs white light cystoscopy.

Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.

The first patient in a trial received oral zelenirstat, a N-myristoyltransferase inhibitor, to determine its safety and tolerability in relapsed/refractory AML.

In a retrospective cohort of patients with severe chronic GVHD, combination axatilimab with other GVHD therapies led to clinical benefit.

A phase 1 study of a personalized cancer vaccine demonstrated antitumor immunity in all treated patients with resected renal cell carcinoma.

In an interview with Peers & Perspectives in Oncology, Michael S. Leapman, MD, MHS, discusses the significance of a 10-year rise in active surveillance and watchful waiting in patients with intermediate-risk prostate cancer.